Abstract: Objective To investigate the efficacy and safety of apatinib mesylate on advanced colon cancer failed in multi-line treatment. Methods From June 2016 to December 2017， 31 cases of advanced colon cancer failed in multi-line treatment received apatinib mesylate monotherapy （n=7） or in combination with chemotherapy （n=24） were enrolled in this study. The initial dose of apatinib was 425 mg／d. Chemotherapy drugs included S-1， oxaliplatin and irinotecan. Clinical efficacy and side effect were evaluated by RECIST1.1 criteria and NCI CTC 3.0 criteria， respectively. Progression-free survival （PFS） was also observed. Results After 4 weeks of apatinib treatment， among the 31 patients could be evaluated， partial remission （PR） was found in 5 cases， stable disease （SD） in 18 cases， and progression disease （PD） in 8 cases. The response rate was 16.1％ （5／31）， and disease control rate was 74.2％ （23／31）. After 8 weeks of apatinib treatment， among the 30 patients could be evaluated， PR was found in 3 cases， SD in 18 cases， and PD in 9 cases. The RR was 10.0％ （3／30）， and DCR was 70.0％ （21／30）. The short-term efficacy between those received apatinib monotherapy or in combination with chemotherapy had no differences （P＞0.05）. The median PFS of 31 patients was 3.5 months. There was no significant difference in PFS between different sex， age， primary site of tumor， metastatic site of tumor and whether in combination with chemotherapy （P＞0.05）. The main adverse reactions were hypertension， proteinuria， hand-foot syndrome， abnormal liver function， hematological toxicity and fatigue， mainly in grade 1-2. The incidence of hypertension and proteinuria （both 16.1％） was higher than other adverse reactions. Conclusion Apatinib mesylate for patients of advanced colon cancer failed in multi-line treatment is effective， and the adverse reactions are tolerable， which can be regarded as a choice for advanced colon cancer failed in multi-line treatment.

Key words: Colon cancer, Apatinib mesylate, Clinical efficacy, Safety